WallStSmart

Abbott Laboratories (ABT)vsEquinix Inc (EQIX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 387% more annual revenue ($45.13B vs $9.26B). EQIX leads profitability with a 14.6% profit margin vs 13.9%. ABT appears more attractively valued with a PEG of 1.39. ABT earns a higher WallStSmart Score of 56/100 (C).

ABT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.5Value: 5.3Quality: 4.8
Piotroski: 3/9

EQIX

Buy

50

out of 100

Grade: C-

Growth: 6.7Profit: 6.5Value: 2.0Quality: 3.5
Piotroski: 3/9Altman Z: 0.55
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTFair Value (-3.5%)

Margin of Safety

-3.5%

Fair Value

$87.68

Current Price

$90.79

$3.11 premium

UndervaluedFair: $87.68Overvalued
EQIXSignificantly Overvalued (-38.5%)

Margin of Safety

-38.5%

Fair Value

$626.41

Current Price

$1082.83

$456.42 premium

UndervaluedFair: $626.41Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT2 strengths · Avg: 8.5/10
Market CapQuality
$158.70B9/10

Large-cap with strong market position

Free Cash FlowQuality
$2.63B8/10

Generating 2.6B in free cash flow

EQIX3 strengths · Avg: 8.3/10
Market CapQuality
$106.79B9/10

Large-cap with strong market position

Operating MarginProfitability
21.5%8/10

Strong operational efficiency at 21.5%

EPS GrowthGrowth
22.9%8/10

Earnings expanding 22.9% YoY

Areas to Watch

ABT3 concerns · Avg: 3.0/10
P/E RatioValuation
25.6x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

EPS GrowthGrowth
-19.7%2/10

Earnings declined 19.7%

EQIX4 concerns · Avg: 2.5/10
Debt/EquityHealth
1.613/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
4.912/10

Expensive relative to growth rate

P/E RatioValuation
74.6x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap, Free Cash Flow. PEG of 1.39 suggests the stock is reasonably priced for its growth.

Bull Case : EQIX

The strongest argument for EQIX centers on Market Cap, Operating Margin, EPS Growth.

Bear Case : ABT

The primary concerns for ABT are P/E Ratio, Piotroski F-Score, EPS Growth.

Bear Case : EQIX

The primary concerns for EQIX are Debt/Equity, Piotroski F-Score, PEG Ratio. A P/E of 74.6x leaves little room for execution misses. Debt-to-equity of 1.61 is elevated, increasing financial risk.

Key Dynamics to Monitor

EQIX carries more volatility with a beta of 1.00 — expect wider price swings.

EQIX is growing revenue faster at 8.1% — sustainability is the question.

ABT generates stronger free cash flow (2.6B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ABT scores higher overall (56/100 vs 50/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

Equinix Inc

REAL ESTATE · REIT - SPECIALTY · USA

Equinix, Inc. is an American multinational company headquartered in Redwood City, California, that specializes in Internet connection and data centers.

Visit Website →

Want to dig deeper into these stocks?